Assembly Biosciences, Inc. (NASDAQ:ASMB) Sees Significant Decline in Short Interest

Assembly Biosciences, Inc. (NASDAQ:ASMB) was the recipient of a significant decrease in short interest in the month of July. As of July 15th, there was short interest totalling 14,400 shares, a decrease of 23.8% from the June 30th total of 18,900 shares. Currently, 0.3% of the shares of the stock are sold short. Based on an average daily volume of 16,600 shares, the days-to-cover ratio is currently 0.9 days.

Assembly Biosciences Stock Performance

Assembly Biosciences stock traded up $0.10 during mid-day trading on Friday, hitting $14.94. The company’s stock had a trading volume of 6,247 shares, compared to its average volume of 14,421. The business has a 50 day moving average price of $14.75 and a 200-day moving average price of $13.27. Assembly Biosciences has a 12 month low of $7.69 and a 12 month high of $20.04.

Assembly Biosciences (NASDAQ:ASMB) last released its quarterly earnings data on Wednesday, May 8th. The biopharmaceutical company reported ($1.66) EPS for the quarter, topping the consensus estimate of ($2.74) by $1.08. The company had revenue of $5.79 million during the quarter. Research analysts expect that Assembly Biosciences will post -12.65 EPS for the current year.

Insider Transactions at Assembly Biosciences

In other Assembly Biosciences news, major shareholder Alexander Schornstein acquired 4,438 shares of the company’s stock in a transaction that occurred on Friday, July 5th. The stock was bought at an average price of $12.52 per share, with a total value of $55,563.76. Following the completion of the purchase, the insider now owns 693,113 shares of the company’s stock, valued at $8,677,774.76. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, major shareholder Alexander Schornstein acquired 4,438 shares of the firm’s stock in a transaction that occurred on Friday, July 5th. The shares were bought at an average cost of $12.52 per share, for a total transaction of $55,563.76. Following the completion of the transaction, the insider now owns 693,113 shares in the company, valued at $8,677,774.76. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director John G. Mchutchison sold 2,117 shares of Assembly Biosciences stock in a transaction that occurred on Thursday, May 23rd. The shares were sold at an average price of $14.93, for a total transaction of $31,606.81. Following the sale, the director now owns 19,104 shares of the company’s stock, valued at $285,222.72. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 5,514 shares of company stock valued at $76,055. 5.10% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Assembly Biosciences

An institutional investor recently bought a new position in Assembly Biosciences stock. Marquette Asset Management LLC purchased a new position in Assembly Biosciences, Inc. (NASDAQ:ASMB) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 54,464 shares of the biopharmaceutical company’s stock, valued at approximately $45,000. Marquette Asset Management LLC owned 0.08% of Assembly Biosciences at the end of the most recent reporting period. 19.92% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the company. HC Wainwright reiterated a “neutral” rating on shares of Assembly Biosciences in a report on Thursday, June 20th. StockNews.com upgraded shares of Assembly Biosciences from a “hold” rating to a “buy” rating in a research report on Friday, May 10th.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc, a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.